BTK inhibitors have transformed B-cell malignancy treatment, with distinct resistance mechanisms linked to specific inhibitors. Covalent inhibitors often lead to BTK C481 mutations, while non-covalent ...
MedPage Today on MSN
Next-gen BCL2 inhibitor approved for aggressive lymphoma
Sonrotoclax (Beqalzi) indicated for relapsed or refractory mantle cell lymphoma ...
A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3. This is an ASCO ...
Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programsPresentations reinforce potential of degraders ...
Protein kinases are the molecular switches of the cell. They control growth, division, communication, and survival by attaching phosphate groups to other proteins. When these switches are stuck in the ...
NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...
Please provide your email address to receive an email when new articles are posted on . In this Healio Video Perspective from the Retina Society meeting, Sumit Sharma, MD, of Cole Eye Institute ...
BTK inhibitors increase infection risk in B-cell lymphoma patients, necessitating proactive monitoring and prophylactic strategies. BTK inhibition affects immune functions, impairing pathogen ...
Merck, known as MSD outside of the United States and Canada, announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (Terns). “The Terns acquisition reflects Merck’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results